The potential for micrin-related medicaments to make a contribution to reducing human suffering is significant. In pursuit of this potential the company has spent about £3.0m so far on its research. This has mainly consisted of investment funding, but includes grants from the UK government in the form of SMART Feasibility and Development Awards, received after third-party due diligence reviews.
New funds are sought periodically from private sources to propel the research, extend the micrin patent portfolio and to enable the company to outlicense its technology to pharmaceutical and biotech industry partners.
The aim of outlicensing is to achieve cash self-sufficiency, enabling the return of monies to shareholders as expediently as possible. Endocrine's aim is to do well by its shareholders, by doing good in the world.
Disclaimer: The above statements do not constitute an offer or invitation to the public to subscribe for or purchase any equity share capital of any company.
Copyright @ 2018 Endocrine Pharmaceuticals Ltd.. All Rights Reserved
Site designed and maintained by Ben Philip - email@example.com